Rankings
▼
Calendar
DNLI
Denali Therapeutics Inc.
$3B
FY 2019 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$27M
-79.3% YoY
Gross Profit
$27M
100.0% margin
Operating Income
-$213M
-799.1% margin
Net Income
-$198M
-740.7% margin
EPS (Diluted)
$-2.07
Cash Flow
Operating Cash Flow
-$152M
Free Cash Flow
-$169M
Stock-Based Comp.
$38M
Balance Sheet
Total Assets
$553M
Total Liabilities
$158M
Stockholders' Equity
$395M
Cash & Equivalents
$79M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$27M
$129M
-79.3%
Gross Profit
$27M
$129M
-79.3%
Operating Income
-$213M
-$46M
-359.7%
Net Income
-$198M
-$36M
-445.3%
← Q4 2018
All Quarters
Q1 2019 →
DNLI FY 2019 Earnings — Denali Therapeutics Inc. Revenue & Financial Results | Market Cap Arena